Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jacksonville, Florida 32224


RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with liver metastases.

Study summary:

OBJECTIVES: - To identify the maximum tolerated dose of stereotactic radiation therapy in patients with hepatic metastases. - To determine the toxicity and adverse events profile of this patient population. - To examine patient response, treatment effect on blood chemistry, and hematology values and patient quality-of-life in this patient population. OUTLINE: Patients are stratified according to stereotactic radiotherapy level (1 vs 2 vs 3) and the number of liver lesions present (1-2 vs 3-5 vs > 5). Patients undergo percutaneous placement of metallic fiducial markers within the liver for stereotactic targeting and planning. Patients then undergo 1 fraction of stereotactic radiotherapy within 1 week of the marker placement. Patients complete Brief Pain Inventory and Brief Fatigue Inventory questionnaires to assess quality of life at weeks 2, 4, 6, 8 and months 3, 6, and 9 after completion of study treatment. After completion of study treatment, patients are followed for at least 8 weeks.


DISEASE CHARACTERISTICS: - Metastatic liver lesion ≤ 5 cm in dimension - Willing and able to undergo percutaneous placement of localization seeds PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - Life expectancy ≥ 12 weeks - Platelet count ≥ 75,000/µL - Hemoglobin ≥ 9 g/dL - ANC ≥ 1,500/mL - Total bilirubin ≤ 1.5 x upper limit of normal (ULN) - AST ≤ 3 x ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Able to complete questionnaires alone or with assistance - No medical, social, or economic circumstance, that is likely to prevent adherence with the protocol PRIOR CONCURRENT THERAPY: - No prior radiation therapy to the liver - No chemotherapy ≤ 4 weeks prior to registration - Able to safely go without chemotherapy for 4 weeks after stereotactic radiotherapy (e.g., patients must not have or need chemotherapy in the 8 weeks [4 weeks prior to and 4 weeks after registration] surrounding stereotactic radiotherapy



Primary Contact:

Principal Investigator
Laura A. Vallow, MD
Mayo Clinic

Backup Contact:


Location Contact:

Jacksonville, Florida 32224
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.